Multiple Myeloma

Current Problems in Cancer

Volumn 33, Issue 1, 2009, Pages 7-64

  Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CARFILZOMIB; CIPROFLOXACIN; CISPLATIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISTARAL; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; HOLMIUM; IMMUNOGLOBULIN; LENALIDOMIDE; LEVOFLOXACIN; LEXIDRONAM SAMARIUM SM 153; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NEUROSEDYN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMIDRONIC ACID; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; STEROID; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WARFARIN; ZOLEDRONIC ACID;

ANEMIA; ARTICLE; BONE LESION; BONE PAIN; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HERPES ZOSTER; HUMAN; HYPERCALCEMIA; HYPOTHYROIDISM; IMMUNOGLOBULIN DEFICIENCY; INFECTION; JAW OSTEONECROSIS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; RASH; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; SYMPTOM; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS;

CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA;

EID: 60849108332     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2009.01.001     Document Type: Article

References (291)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
2. Rajkumar S.V., and Kyle R.A. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80 (2005) 1371-1382
3. Kyle R.A., Therneau T.M., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.F., et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med 346 (2002) 564-569
4. Kyle R.A., Therneau T.M., Rajkumar S.V., Larson D.R., Plevak M.F., Offord J.R., et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354 (2006) 1362-1369
5. Kyle R.A., Therneau T.M., Rajkumar S.V., Larson D.R., Plevak M.F., and Melton III L.J. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer 101 (2004) 2667-2674
6. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer Statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
7. Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispenzieri A., et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 78 (2003) 21-33
8. Solly S. Remarks on the pathology of mollities ossium with cases. Medica-Chirurgical Transactions of London 27 (1844) 435-461
9. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Medica-Chirurgical Transactions of London 33 (1850) 211-232
10. Clamp J.R. Some aspects of the first recorded case of multiple myeloma. Lancet 2 (1967) 1354-1356
11. Bence Jones H. Chemical pathology. Lancet 2 (1847) 88-92
12. Bence Jones H. On the new substance occurring in the urine of a patient with mollities ossium. Philos Trans R Soc Land 138 (1848) 55-62
13. Waldeyer W. Ueber bindegewebszellen. Archiv fur Microbiologie and Anatomie 11 (1875) 176-194
14. Wright J.H. A case of multiple myeloma. Trans Assoc Am Phys 15 (1900) 137-147
15. Geschickter C.F., and Copeland M.M. Multiple myeloma. Arch Surg 16 (1928) 807-863
16. Perlzweig W.A., Delrue G., and Geschicter C. Hyperproteinemia associated with multiple myelomas: report of an unusual case. J Am Med Assoc 90 (1928) 755-757
17. Fleischer R. XXIV. Ueber das Vorkommen des sogenannten Bence Jones' schen Eiweisskorpers im normalen Knochenmark. Arch Pathol Anatom Physiol Klin Med 80 (1880) 842-849
18. Bayne-Jones S., and Wilson D.W. Immunological reactions of Bence-Jones proteins. II. Differences between Bence-Jones proteins from various sources. Bull Johns Hopkins Hosp 33 (1922) 119-125
19. Korngold L., and Lipari R. Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins. Cancer 9 (1956) 262-272
20. Tiselius A. A new apparatus for electrophoretic analysis of colloidal mixtures. Transactions of the Faraday Society 33 (1937) 524
21. Tiselius A., and Kabat E.A. Electrophoretic study of immune sera and purified antibody preparation. J Exp Med 69 (1939) 119-131
22. Longsworth L.G., Shedlovsky T., and MacInnes D.A. Electrophoretic patterns of normal and pathological human blood, serum, and plasma. J Exp Med 70 (1939) 399-413
23. Grabar P., and Williams C.A. Methode permettant l'etude conjuguee des proprietes electrophoretiques et immunochimiques d'un melange de proteines; application au serum sanguin. Biochim Biophys Acta 10 (1953) 193-194
24. Wilson A.T. Direct immunoelectrophoresis. J Immunol 92 (1964) 431-434
25. Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect 56 (1960) 211-231
26. Kyle R.A. Multiple myeloma: an odyssey of discovery. Br J Haematol 111 (2000) 1035-1044
27. Alwall N. Urethane and stilbamidine in multiple myeloma: report on two cases. Lancet 2 (1947) 388-389
28. Holland J.R., Hosley H., Scharlau C., Carbone P.P., Frei III E., Brindley C.O., et al. A controlled trial of urethane treatment in multiple myeloma. Blood 27 (1966) 328-342
29. Blokhin N., Larionov L., Perevodchikova N., Chebotareva L., and Merkulova N. Clinical experiences with sarcolysin in neoplastic diseases. Ann N Y Acad Sci 68 (1958) 1128-1132
30. Bergsagel D.E., Sprague C.C., Austin C., and Griffith K.M. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep 21 (1962) 87-99
31. Salmon S.E., Shadduck R.K., and Schilling A. Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer Chemother Rep 51 (1967) 179-187
32. Mass R.E. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep 16 (1962) 257-259
33. McIntyre O.R., Pajak T.F., Kyle R.A., Cornwell III G.G., and Leone L. Response rate and survival in myeloma patients receiving prednisone alone. Med Pediatr Oncol 13 (1985) 239-243
34. Alexanian R., Haut A., Khan A.U., Lane M., McKelvey E.M., Migliore P.J., et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208 (1969) 1680-1685
35. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16 (1998) 3832-3842
36. Thomas E.D., Lochte Jr. H.L., Lu W.C., and Ferrebee J.W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257 (1957) 491-496
37. McElwain T.J., and Powles R.L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2 (1983) 822-824
38. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121 (2003) 749-757
39. Rajkumar S.V., Dispenzieri A., and Kyle R.A. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clinic Proc 81 (2006) 693-703
40. Jego G., Bataille R., Geffroy-Luseau A., Descamps G., and Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20 (2006) 1130-1137
41. Bohnhorst J., Rasmussen T., Moen S.H., Fløttum M., Knudsen L., Borset M., et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20 (2006) 1138-1144
42. Mantovani A., and Garlanda C. Inflammation and multiple myeloma: the Toll connection. Leukemia 20 (2006) 937-938
43. Perez-Andres M., Almeida J., Martin-Ayuso M., Moro M.J., Martin-Nuñez G., Galende J., et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 19 (2005) 449-455
44. Rawstron A.C., Fenton J.A., Ashcroft J., English A., Jones R.A., Richards S.J., et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 96 (2000) 3880-3886
45. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
46. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2 (2002) 175-187
47. Bergsagel P.L., and Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 20 (2001) 5611-5622
48. Fonseca R., Bailey R.J., Ahmann G.J., Rajkumar S.V., Hoyer J.D., Lust J.A., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100 (2002) 1417-1424
49. Drach J., Angerler J., Schuster J., Rothermundt C., Thalhammer R., Haas O.A., et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86 (1995) 3915-3921
50. Fonseca R., Aguayo P., Ahmann G.J., Jalal S.M., Rajkumar S.V., Kyle R.A., et al. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes. Blood 94 suppl 1 (1999) 663a (A 2943)
51. Rajkumar S.V. MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management. Hematology Am Soc Hematol Educ Program (2005) 340-345
52. Chng W.J., Van Wier S.A., Ahmann G.J., Winkler J.M., Jalal S.M., Bergsagel P.L., et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106 (2005) 2156-2161
53. Magrangeas F., Lode L., Wuilleme S., Minvielle S., and Avet-Loiseau H. Genetic heterogeneity in multiple myeloma. Leukemia 19 (2005) 191-194
54. Kaufmann H., Ackermann J., Baldia C., Nösslinger T., Wieser R., Seidl S., et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 18 (2004) 1879-1882
55. Rajkumar S.V., Mesa R.A., Fonseca R., Schroeder G., Plevak M.F., Dispenzieri A., et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8 (2002) 2210-2216
56. Kumar S., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., Wellik T.E., et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 101 (2003) 1715-1717
57. Galea H.R., and Cogne M. GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model. Clin Exp Immunol 129 (2002) 247-253
58. Vacca A., Ria R., Ribatti D., Semeraro F., Djonov V., Di Raimondo F., et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88 (2003) 176-185
59. Roodman G.D. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 17 (2002) 1921-1925
60. Roodman G.D. Mechanisms of bone metastasis. [see comment]. N Engl J Med 350 (2004) 1655-1664
61. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. [see comment]. N Engl J Med 349 (2003) 2483-2494
62. Katzmann J.A., Dispenzieri A., Kyle R., Snyder M.R., Plevak M.F., Larson D.R., et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 81 (2006) 1575-1578
63. Kyle R.A., and Rajkumar S.V. Monoclonal gammopathy of undetermined significance. Br J Haematol 134 (2006) 573-589
64. Katzmann J.A., Clark R.J., Abraham R.S., Bryant S., Lymp J.F., Bradwell A.R., et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48 (2002) 1437-1444
65. Bradwell A.R., Carr-Smith H.D., Mead G.P., Harvey T.C., and Drayson M.T. Serum test for assessment of patients with Bence Jones myeloma. Lancet 361 (2003) 489-491
66. Drayson M., Tang L.X., Drew R., Mead G.P., Carr-Smith H., and Bradwell A.R. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97 (2001) 2900-2902
67. Lachmann H.J., Gallimore R., Gillmore J.D., Carr-Smith H.D., Bradwell A.R., Pepys M.B., et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122 (2003) 78-84
68. Abraham R.S., Clark R.J., Bryant S.C., Lymp J.F., Larson T., Kyle R.A., et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 48 (2002) 655-657
69. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 (1975) 842-854
70. Kyle R.A. Prognostic factors in multiple myeloma. Stem Cells 2 (1995) 56-63
71. Rapoport B.L., Falkson H.C., and Falkson G. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients. S Afr Med J 79 (1990) 65-67
72. Greipp P.R., San Miguel J.F., Durie B.G., Crowley J.J., Barlogie B., Bladé J., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
73. Rajkumar S.V., and Greipp P.R. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 13 (1999) 1295-1314
74. Tricot G., Sawyer J.R., Jagannath S., Desikan K.R., Siegel D., Naucke S., et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15 (1997) 2659-2666
75. Greipp P.R. Prognosis in myeloma. [Review]. Mayo Clin Proc 69 (1994) 895-902
76. Facon T., Avet-Loiseau H., Guillerm G., Moreau P., Genevieve F., Zandecki M., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 (2001) 1566-1571
77. Greipp P.R., Leong T., Bennett J.M., Gaillard J.P., Klein B., Stewart J.A., et al. Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 91 (1998) 2501-2507
78. Greipp P.R., Lust J.A., O'Fallon W.M., Katzmann J.A., Witzig T.E., and Kyle R.A. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. [see comments]. Blood 81 (1993) 3382-3387
79. Dispenzieri A., Rajkumar S.V., Gertz M.A., Fonseca R., Lacy M.Q., Bergsagel P.L., et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus Statement. Mayo Clin Proc 82 (2007) 323-341
80. Blade J., Samson D., Reece D., Apperley J., Björkstrand B., Gahrton G., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant). Br J Haematol 102 (1998) 1115-1123
81. Durie B.G.M., Harousseau J.-L., Miguel J.S., Bladé J., Barlogie B., Anderson K., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
82. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddiemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. [see comments]. N Engl J Med 341 (1999) 1565-1571
83. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
84. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. [see comment]. N Engl J Med 352 (2005) 2487-2498
85. Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
86. Richardson P.G., Blood E., Mitsiades C.S., Jagannath S., Zeldenrust S.R., Alsina M., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 (2006) 3458-3464
87. Lenz W. A short history of thalidomide embryopathy. Teratology 38 (1988) 203-215
88. Lenz W. A personal perspective on the thalidomide tragedy. Teratology 46 (1992) 417-418
89. Stephens T., and Brynner R. Dark Remedy. The Impact of Thalidomide and Its Revival As a Vital Medicine (2001), Perseus Publishing, Cambridge, MA
90. Lenz W. Thalidomide and congenital abnormalities. Lancet 1 (1962) 45
91. McBride W.G. Thalidomide and congenital abnormalities. Lancet 2 (1961) 1358
92. Geraghty K. Profile of a role model: Francis Oldham Kelsey, MD, PhD. Vol. 2003 (ed http://www.ama-assn.org/ama/pub/printcat/5335.html): American Medical Association, 2001.
93. Rogerson G. Thalidomide and congenital abnormalities. Lancet 1 (1962) 691
94. Woodyatt P.B. Thalidomide. Lancet 1 (1962) 750
95. Grabstad H., and Golbey R. Clinical experience with thalidomide in patients with cancer. Clin Pharmacol Therap 6 (1965) 298-302
96. Olson K.B., Hall T.C., Horton J., Khung C.L., and Hosley H.F. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 6 (1965) 292-297
97. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6 (1965) 303-306
98. Iyer C.G., Languillon J., Ramanujam K., Tarabini-Castellani G., De las Aguas J.T., et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 45 (1971) 719-732
99. Mascaro J.M., Lecha M., and Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Arch Dermatol 115 (1979) 636-637
100. Lim S.H., McWhannell A., Vora A.J., and Boughton B.J. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet 1 (1988) 117
101. Saurat J.H., Camenzind M., Helg C., and Chapuis B. Thalidomide for graft-versus-host disease after bone marrow transplantation. Lancet 1 (1988) 359
102. Vogelsang G.B., Santos G.W., Colvin O.M., and Chen T. Thalidomide for graft-versus-host disease. Lancet 1 (1988) 827
103. Vogelsang G.B., Wells M.C., Santos G.W., Chen T.L., and Hess A.D. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant Proc 20 (1988) 226-228
104. Ringden O., Aschan J., and Westerberg L. Thalidomide for severe acute graft-versus-host disease. Lancet 2 (1988) 568
105. Youle M., Clarbour J., Farthing C., Connolly M., Hawkins D., Slaughton R., et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ 298 (1989) 432
106. Reyes-Teran G., Sierra-Madero J.G., Martinez del Cerro V., Arroyo-Figueroa H., Pasquetti A., Calva J.J., et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. Aids 10 (1996) 1501-1507
107. Zeldis J.B., Williams B.A., Thomas S.D., and Elsayed M.E. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21 (1999) 319-330
108. Lary J.M., Daniel K.L., Erickson J.D., Roberts H.E., and Moore C.A. The return of thalidomide: can birth defects be prevented?. Drug Saf 21 (1999) 161-169
109. Eriksson T., Bjorkman S., and Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57 (2001) 365-376
110. Stirling D.I. Pharmacology of thalidomide. Semin Hematol 37 (2000) 5-14
111. Eriksson T., Bjorkman S., Roth B., Fyge A., and Hoglund P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7 (1995) 44-52
112. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
113. Kenyon B.M., Browne F., and D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64 (1997) 971-978
114. Barlogie B., Spencer T., Tricot G., Zeldis J., Munshi N., Zangari M., et al. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). Blood 96 (2000) 514a (A2213)
115. Rajkumar S.V., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., Witzig T.E., et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75 (2000) 897-902
116. Kumar S., Gertz M.A., Dispenzieri A., et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. [comment]. Mayo Clin Proc 78 (2003) 34-39
117. Rajkumar S.V., and Witzig T.E. A review of angiogenesis and anti-angiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26 (2000) 351-362
118. Rajkumar S.V., Hayman S., Gertz M.A., Dispenzieri A., Lacy M.Q., Greipp P.R., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20 (2002) 4319-4323
119. Rajkumar S.V., Dispenzieri A., Fonseca R., Lacy M.Q., Geyer S., Lust J.A., et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15 (2001) 1274-1276
120. Rajkumar S.V., Gertz M.A., Lacy M.Q., Dispenzieri A., Fonseca R., Geyer S.M., et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 17 (2003) 775-779
121. Weber D., Rankin K., Gavino M., Delasalle K., and Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21 (2003) 16-19
122. Rajkumar S.V., Gertz M.A., Kyle R.A., and Greipp P.R. Current therapy for multiple myeloma. Mayo Clin Proc 77 (2002) 813-822
123. Anagnostopoulos A., Weber D., Rankin K., Delasalle K., and Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121 (2003) 768-771
124. Dimopoulos M.A., Hamilos G., Zomas A., Gika D., Efstathiou E., Grigoraki V., et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 5 (2004) 112-117
125. Garcia-Sanz R., Gonzalez-Fraile M.I., Sierra M., Lopez C., Gonzalez M., and San Miguel J.F. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J 3 (2002) 43-48
126. Kropff M.H., Lang N., Bisping G., Dominé N., Innig G., Hentrich M., et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 122 (2003) 607-616
127. Coleman M., Leonard J., Lyons L., Pekle K., Nahum K., Pearse R., et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma 43 (2002) 1777-1782
128. Ghobrial I.M., and Rajkumar S.V. Management of thalidomide toxicity. J Support Oncol 1 (2003) 194-205
129. Osman K., Comenzo R., and Rajkumar S.V. Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344 (2001) 1951-1952
130. Zangari M., Anaissie E., Barlogie B., Badros A., Desikan R., Gopal A.V., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
131. Zangari M., Siegel E., Barlogie B., Anaissie E., Saghafifer F., Fassas A., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100 (2002) 1168-1171
132. Zangari M., Saghafifar F., Anaissie E., Badros A., Desikan R., Fassas A., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13 (2002) 187-192
133. Rajkumar S.V., Gertz M.A., and Witzig T.E. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343 (2000) 972-973
134. Badros A.Z., Siegel E., Bodenner D., Zangari M., Zeldis J., Barlogie B., et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 112 (2002) 412-413
135. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98 (2001) 492-494
136. Dimopoulos M.A., Anagnostopoulos A., and Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21 (2003) 4444-4454
137. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 7 (2002) 9-16
138. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28 (2001) 613-619
139. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14 (2002) 628-634
140. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 79 (1994) 13-21
141. Adams J., Palombella V.J., and Elliott P.J. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18 (2000) 109-121
142. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Op Chem Biol 6 (2002) 493-500
143. Hershko A., and Ciechanover A. The ubiquitin system. Annu Rev Biochem 67 (1998) 425-479
144. Varshavsky A. The ubiquitin system. Trend Biochem Sci 22 (1997) 383-387
145. Craiu A., Gaczynska M., Akopian T., Gramm C.F., Fenteany G., Goldberg A.L., et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 272 (1997) 13437-13445
146. Orlowski M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry 29 (1990) 10289-10297
147. Coux O., Tanaka K., and Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65 (1996) 801-847
148. Almond J.B., and Cohen G.M. The proteasome: a novel target for cancer chemotherapy. Leukemia 16 (2002) 433-443
149. Braun B.C., Glickman M., Kraft R., Dahlmann B., Kloetzel P.M., Finley D., et al. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol 1 (1999) 221-226
150. Kloetzel P.M. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2 (2001) 179-187
151. Pickart C.M., and VanDemark A.P. Opening doors into the proteasome. [comment]. Nat Struct Biol 7 (2000) 999-1001
152. Groll M., Bajorek M., Kohler A., Moroder L., Rubin D.M., Huber R., et al. A gated channel into the proteasome core particle. [comment]. Nature Struct Biol 7 (2000) 1062-1067
153. Lowe J., Stock D., Jap B., Zwickl P., Baumeister W., and Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. [comment]. Science 268 (1995) 533-539
154. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59 (1999) 2615-2622
155. Orlowski R.Z., Eswara J.R., Lafond-Walker A., Grever M.R., Orlowski M., and Dang C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58 (1998) 4342-4348
156. Drexler H.C. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 94 (1997) 855-860
157. Delic J., Masdehors P., Omura S., Cosset J.M., Dumont J., Binet J.L., et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. [comment]. Br J Cancer 77 (1998) 1103-1107
158. An B., Goldfarb R.H., Siman R., and Dou Q.P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Diff 5 (1998) 1062-1075
159. Traenckner E.B., Wilk S., and Baeuerle P.A. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 13 (1994) 5433-5441
160. Mori S., Tanaka K., Omura S., and Saito Y. Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway. J Biol Chem 270 (1995) 29447-29452
161. Cusack Jr. J.C., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61 (2001) 3535-3540
162. Russo S.M., Tepper J.E., Baldwin Jr. A.S., Liu R., Adams J., Elliott P., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Rad Oncol Biol Phys 50 (2001) 183-193
163. Shah S.A., Potter M.W., McDade T.P., Ricciardi R., Perugini R.A., Elliott P.J., et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82 (2001) 110-122
164. Teicher B.A., Ara G., Herbst R., Palombella V.J., and Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5 (1999) 2638-2645
165. Frankel A., Man S., Elliott P., Adams J., and Kerbel R.S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6 (2000) 3719-3728
166. Bold R.J., Virudachalam S., and McConkey D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100 (2001) 11-17
167. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 (2001) 3071-3076
168. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gus X., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99 (2002) 14374-14379
169. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
170. LeBlanc R., Catley L.P., Hideshima T., Lentzsch S., Mitsiades C.S., Mitsiades N., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62 (2002) 4996-5000
171. Berenson J.R., Jagannath S., Barlogie B., Siegel D., Alexanian R., Irwin D., et al. Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc Am Soc Clin Oncol 22 (2003) 581
172. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
173. Zangari M., Tricot G., Zeldis J., Eddlemon P., Saghafifar F., and Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood (2001) 775a (A3226)
174. Dimopoulos M.A., Spencer A., Attal M., Prince M., Harousseau J.-L., Dmoszynska A., et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood 106 (2005) 6
175. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E., et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009). Proc Am Soc Clin Oncol 24 (2006) A7521
176. Orlowski R.Z., Nagler A., Sonneveld P., Bladé J., Hajek R., Spencer A., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25 (2007) 3892-3901
177. Streetly M., Jones R.W., Knight R., Rassam S., Gillett D., Singer C., et al. An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma. Blood 102 (2003) 236a
178. Lacy M.Q., Hayman S.R., Gertz M.A., Alfred J.B., Mandrekar S.J., Dispenzieri A., et al. Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 112 (2008) 866
179. Jagannath S., Vij R., Stewart A.K., Somlo G., Jakubowiak A., Reiman T., et al. Initial results of PX-171-003, an open-label, single-arm, phase iI study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 112 (2008) 864
180. Vij R., Wang M., Orlowski R., Stewart A.K., Jagannath S., Kukreti V., et al. Initial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). Blood (ASH Annual Meeting Abstracts) 112 (2008) 865
181. Hideshima T., Chauhan D., Podar K., Schlossman R.L., Richardson P., and Anderson K.C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 28 (2001) 607-612
182. Musto P., Petrucci M.T., Bringhen S., Guglielmelli T., Caravita T., Bongarzoni V., et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 113 (2008) 1588-1595
183. Cavo M., Zamagni E., Tosi P., Tacchetti P., Cellini C., Cangini D., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
184. Fermand J.-P., Jaccard A., Macro M., Uzunhan Y., Allard C., Castaigne S., et al. A Randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs Dex + placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). Blood 108 (2006) 3563
185. Rajkumar S.V., Blood E., Vesole D.H., Fonseca R., and Greipp P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
186. Weber D.M., Gavino M., Delasalle K., Rankin K., Giralt S., and Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 94 suppl 1 (1999) 604a (A 2686)
187. Cavo M., Zamagni E., Tosi P., Cellini C., Cangini D., Tacchetti P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89 (2004) 826-831
188. Rajkumar S.V., Rosiñol L., Hussein M., Catalano J., Jedrzejczak W., Lucy L., et al. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26 (2008) 2171-2177
189. Lokhorst H., van der Holt B., Zweegman S., Von Dem Borne P.A., Bos G.M.J., Croockewit S., et al. Final Analysis of HOVON-50 randomized phase III study on the effect of thalidomide combined with adriamycine, dexamethasone (AD) and high dose melphalan (HDM) in patients with multiple myeloma (MM). ASH Annual Meeting Abstracts 112 (2008) 157
190. Lacy M., Gertz M., Dispenzieri A., Hayman S., Geyer S., Zeldenrust S., et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. Blood 108 (2006) 798
191. Rajkumar S.V., Jacobus S., Callander N., Fonseca R., Vesole D., and Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 108 (2006) 799
192. Richardson P.G., Chanan-Khan A., Schlossman R.L., Munshi N.C., Wen P., Briemberg H., et al. Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM). Blood 104 (2004) 100a (A336)
193. Jagannath S., Durie B.G., Wolf J., Camacho E., Irwin D., Lutzsky J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 (2005) 776-783
194. Harousseau J., Attal M., Leleu X., Troney J., Pegourie B., Stoppa A., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91 (2006) 1498-1505
195. Harousseau J.-L., Marit G., Caillot D., Casassus P., Facon T., Mohty M., et al. VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood 108 (2006) 56
196. Barlogie B., Anaissie E., van Rhee F., Haessler J., Hollmig K., Pineda-Roman M., et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 138 (2007) 176-185
197. Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
198. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Renaud M., et al. Major superiority of melphalan - prednisone (MP) + Thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 106 (2005) 230a (A780)
199. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Pegourie B., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370 (2007) 1209-1218
200. Hulin C., Virion J., Leleu X., Rodon P., Pegourie B., Benboubker L., et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. J Clin Oncol (Meeting Abstracts) 25 (2007) 8001
201. Wijermans P., Schaafsma M., van Norden Y., Ammerlaan R., Wittebol S., Sinnige H., et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study. Blood (ASH Annual Meeting Abstracts) 112 (2008) 649
202. Waage A., Gimsing P., Juliusson G., Turesson I., and Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. ASH Annual Meeting Abstracts 110 (2007) 78
203. Palumbo A., Bringhen S., Liberati A.M., Caravita T., Falcone A., Callea V., et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112 (2008) 3107-3114
204. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulis M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 (2008) 906-917
205. Palumbo A., Falco P., Corradini P., Falcone A., Di Raimondo F., Giuliani N., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network. J Clin Oncol 25 (2007) 4459-4465
206. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
207. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
208. Blade J., Vesole D.H., and Gertz M. Transplantation for multiple myeloma: who, when, how often?. Blood 102 (2003) 3469-3477
209. Kumar A., Loughran T., Alsina M., Durie B.G., and Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 4 (2003) 293-304
210. Moreau P., Facon T., Attal M., Hulin C., Michallet M., Maloisel F., et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 99 (2002) 731-735
211. Bensinger W., Giralt S., Holmberg L., Eary J., Goodman M., Podoloff D., et al. 166H0-DOTMP and high-dose melphalan before autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Hematol J 4 suppl 1 (2003) S215-S216
212. Dispenzieri A., Wiseman G.A., Lacy M.Q., Geyer S., Litzow M.R., Tefferi A., et al. A phase II study of high dose 153-samarium EDTMP (153-Sm EDMTP) and melphalan for peripheral stem cell transplantation (PBSCT) in multiple myeloma (MM). Blood 102 (2003) 982a
213. Fermand J.P., Ravaud P., Chevret S., Divine M., Leblond V., Berlanger C., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment?. Results of a multicenter sequential randomized clinical trial. Blood 92 (1998) 3131-3136
214. Facon T., Mary J.Y., Harousseau J.L., Attal M., Bosly A., Michaux J.L., et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol. Blood 88 suppl 1 (1996) 685a
215. Barlogie B., Kyle R., Anderson K., Greipp P., Lazarus H., Jacobson J., et al. Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup Trial S9321. Blood 102 (2003) 42a
216. Blade J., Sureda A., Ribera J.M., Diaz-Mediavilla J., Garca-Laraa J., et al. High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from PETHEMA after a median follow-up of 66 months. Blood 102 (2003) 42a
217. Rajkumar S.V., Fonseca R., Lacy M.Q., Witzig T.E., Lust J.A., Greipp P.R., et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 23 (1999) 1267-1272
218. Blade J., and Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. [Review]. Acta Oncol 39 (2000) 843-847
219. Barlogie B., Jagannath S., Vesole D.H., Naucke S., Cheson B., Mattox S., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
220. Barlogie B., Jagannath S., Desikan K.R., Mattox S., Vesole D., Siegel D., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93 (1999) 55-65
221. Attal M., Harousseau J.L., Facon T., Guilhot F., Doyen C., Fuzibet J.G., et al. Double Autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the "Intergroupe Francophone du Myelome" (IFM 94). Blood 100 (2002) 5a
222. Cavo M., Cellini C., Zamagni E., Tosi P., Cangini D., Tacchetti P., et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood 104 (2004) 155a (A536)
223. Fermand J.P., Alberti C., and Marolleau J.P. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Hematol J 4 suppl 1 (2003) S59
224. Goldschmidt H. Single vs. tandem autolgous transplantation in multiple myeloma: the GMMG experience. Hematol J 4 suppl 1 (2003) S61
225. Sirohi B., Powles R., Singhal S., Treleaven J., Kulkarni S., Horton C., et al. High-dose melphalan and second autografts for myeloma relapsing after one autograft: results equivalent to tandem autotransplantation. Blood 98 (2001) 402a (A1690)
226. Mehta J., and Singhal S. Graft-versus-myeloma. Bone Marrow Transplant 22 (1998) 835-843
227. Gahrton G., Svensson H., Cavo M., Apperly J., Bacigalupo A., Björkstrand B., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113 (2001) 209-216
228. Einsele H., Schafer H.J., Hebart H., Bader P., Meisner C., Plasswilm L., et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 121 (2003) 411-418
229. Crawley C., Lalancette M., Szydlo R., Gilleece M., Peggs K., MacKinnon S., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
230. Maloney D.G., Molina A.J., Sahebi F., Stockerl-Goldstein K.E., Sandmaier B.M., Bensinger W., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454
231. Garban F., Attal M., Michallet M., Hulin C., Bourhis J.H., Yakoab-Agha I., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
232. Bruno B., Rotta M., Patriarca F., Mordini N., Allione B., Carnevale-Sehianca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
233. Rosinol L., Perez-Simon J.A., Sureda A., de la Rubia J., de Arriba F., Lahuerta J.J., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112 (2008) 3591-3593
234. Mateos M.-V., Hernandez J.-M., Hernandez M.-T., Gutiérrez N.C., Palomera L., Fuertes M., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 (2006) 2165-2172
235. Jagannath S., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21 (2006) 151-157
236. Sagaster V., Ludwig H., Kaufmann H., Odelga V., Zojer N., Ackermann J., et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 21 (2006) 164-168
237. Myeloma Trialists' Collaborative G. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113 (2001) 1020-1034
238. Berenson J.R., Crowley J.J., Grogan T.M., Zangmeister J., Briggs A.D., Mills G.M., et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99 (2002) 3163-3168
239. Attal M., Harousseau J.-L., Leyvraz S., Doyen C., Hulin C., Benboubker L., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (2006) 3289-3294
240. Spencer A., Prince M., Roberts A.W., Bradstock K.F., and Prosser I.W. First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6). ASH Annual Meeting Abstracts 108 (2006) 58
241. Offidani M., Polloni C., Corvatta L., Piersantelli M.-N., Galieni P., Visani G., et al. Thalidomide-dexamethasone vs interferon-{alpha}-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma (MM): final analysis of a prospective, randomized study. ASH Annual Meeting Abstracts 110 (2007) 532
242. Abdelkefi A., Ladeb S., Torjman L., Othman T.B., Lakhal A., Romdhane N.B., et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111 (2008) 1805-1810
243. Maiolino A., Hungria V.T., Oliveira-Duarte G., Oliviera L.C., Mercante D.R., Miranda E., et al. Thalidomide + dexamethasone as maintenance after single autologous stem cell transplantation improves progression-free survival (PFS) in advanced multiple myeloma. A Prospective Brazilian Randomized Trial. ASH Annual Meeting Abstracts 112 (2008) 3703
244. Morgan G.J., Jackson G.H., Davies F.E., Drayson M.T., Owen R.G., Gregory W.M., et al. Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX Maintenance Randomisation. Blood (ASH Annual Meeting Abstracts) 112 (2008) 656
245. Barlogie B., Tricot G., Anaissie E., Shaughnessy J., Rasmussen E., van Rhee F., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. [see comment]. N Engl J Med 354 (2006) 1021-1030
246. Gertz M.A., Lacy M.Q., Inwards D.J., Chen M.G., Pineda A.A., Gastineu D.A., et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant 23 (1999) 221-226
247. Alexanian R., Barlogie B., and Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105 (1986) 8-11
248. Gertz M.A., Garton J.P., Greipp P.R., Witzig T.E., and Kyle R.A. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 9 (1995) 2115-2118
249. Gucalp R., Theriault R., Gill I., Madajewicz S., Chapman R., Navari R., et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 154 (1994) 1935-1944
250. Major P., Lortholary A., Hon J., Abdi E., Mills G., Menssen H.D., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 (2001) 558-567
251. Berenson J.R., Lichtenstein A., Porter L., Dimopoulis M.A., Bordoni R., George S., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. [see comments]. N Engl J Med 334 (1996) 488-493
252. Berenson J.R., Rosen L.S., Howell A., Porter L., Coleman R.E., Morley W., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. [Published erratum in Cancer 2001;91(10):1956]. Cancer 91 (2001) 1191-1200
253. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastatses in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase II, double blind, comparative trial. Cancer J 7 (2001) 377-387
254. Berenson J.R., Hillner B.E., Kyle R.A., Anderson K., Lipton A., Yee G.C., et al. American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719-3736
255. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. [see comment]. J Oral Maxillofac Surg 61 (2003) 1115-1117
256. Kademani D., Koka S., Lacy M.Q., and Rajkumar S.V. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81 (2006) 1100-1103
257. Badros A., Weikel D., Salama A., Goloubera O., Schneider A., Rappoport A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
258. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
259. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
260. Lacy M.Q., Dispenzieri A., Gertz M.A., Greipp P.R., Gollbach K.L., Hayman S.R., et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81 (2006) 1047-1053
261. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., Melakopoulis I., Gika D., Moulopoulos L.A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968-971
262. Melton III L.J., Kyle R.A., Achenbach S.J., Oberg A.L., and Rajkumar S.V. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20 (2005) 487-493
263. Fourney D.R., Schomer D.F., Nader R., Chlan-Fourney J., Suki D., Ahrar K., et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 98 (2003) 21-30
264. Yussim E., Schwartz E., Sidi Y., and Ehrenfeld M. Acute renal failure precipitated by non-steroidal anti-inflammatory drugs (NSAIDs) in multiple myeloma. Am J Hematol 58 (1998) 142-144
265. Wu M.J., Kumar K.S., Kulkarni G., and Kaiser H. Multiple myeloma in naproxen-induced acute renal failure. N Engl J Med 317 (1987) 170-171
266. Johnson W.J., Kyle R.A., Pineda A.A., O'Brien P.C., and Holley K.E. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150 (1990) 863-869
267. Garton J.P., Gertz M.A., Witzig T.E., Greipp P.R., Lust J.A., Schroeder G., et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155 (1995) 2069-2074
268. Dammacco F., Castoldi G., and Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. [Published erratum in Br J Haematol 2001;114(3):738]. Br J Haematol 113 (2001) 172-179
269. Oken M.M., Pomeroy C., Weisdorf D., and Bennett J.M. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100 (1996) 624-628
270. Gertz M.A., and Kyle R.A. Hyperviscosity syndrome. J Intensive Care Med 10 (1995) 128-141
271. Rajkumar S.V., and Kyle R.A. Multiple myeloma: diagnosis and treatment. [see comment]. Mayo Clin Proc 80 (2005) 1371-1382
272. Kyle R.A., Therneau T.M., Rajkumar S.V., Remstein E.D., Offord J.R., Larson D.R., et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102 (2003) 3759-3764
273. Gobbi P.G., Baldini L., Broglia C., Goldaniga M., Comelli M., Morel P., et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. Clin Cancer Res 11 (2005) 1786-1790
274. Kyle R.A., Therneau T.M., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.F., et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol 30 (2003) 169-171
275. Baldini L., Goldaniga M., Guffanti A., Broglia C., Cortelazzo S., Rossi A., et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 23 (2005) 4662-4668
276. Owen R.G., Treon S.P., Al-Katib A., Fonseca R., Greipp P.R., McMaster M.L., et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30 (2003) 110-115
277. Dimopoulos M.A., Moulopoulos L.A., Maniatis A., and Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96 (2000) 2037-2044
278. Dimopoulos M.A., Kiamouris C., and Moulopoulos L.A. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 13 (1999) 1249-1257
279. Dispenzieri A., Kyle R.A., Lacy M.Q., Rajkumar S.V., Therneau T.M., Larson D.R., et al. POEMS syndrome: definitions and long-term outcome. Blood 101 (2003) 2496-2506
280. Browman G.P., Bergsagel D., Sicheri D., Or S., Wilson K.S., Rubin S., et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13 (1995) 2354-2360
281. Fassas A.B., Spencer T., Sawyer J., Zangari M., Lee C.K., Anaissie E., et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 118 (2002) 1041-1047
282. Barlogie B., Kyle R.A., Anderson K.C., Greipp P.R., Lazarus H.M., Hurd D.D., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
283. Attal M., Harousseau J.L., Facon T., Guilhot F., Doyen C., Fuzibet J.G., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. [see comment]. N Engl J Med 349 (2003) 2495-2502
284. Blade J., Rosinol L., Sureda A., Ribera J.M., Diaz-Mediavilla J., Garcia-Larana J., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
285. Rajkumar S.V., Jacobus S., Callander N., Fonseca R., Vesole D., Williams M., et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial Coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts 110 (2007) 74
286. Harousseau J.L., Mathiot C., Attal M., Marit G., Caillot D., Mohty M.M.M., et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 Trial. ASH Annual Meeting Abstracts 110 (2007) 450
287. Cavo M., Patriarca F., Tacchetti P., Galli M., Perrone G., Petrucci M.T., et al. Bortezomib (velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 110 (2007) 73
288. Harousseau J.L., and Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev 16 (2002) 245-253
289. Fermand J.P., Katsahian S., Divine M., Leblond V., Dreyfus F., Macro M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
290. Palumbo A., Bringhen S., Petrucci M.T., Musto P., Rossini F., Nunzi M., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104 (2004) 3052-3057
291. Sonneveld P., van der Holt B., Vellenga E., Croockewit S., Verhoef G., Segeren C., et al. Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 Trial. ASH Annual Meeting Abstracts 106 (2005) 2545